SCHEMBL6328328

SCHEMBL6328328

CCCC(=O)Oc1nc(-c2ccc(OC)cc2)no1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.55
ATM Q13315 1/20 0.55
KMT2A Q03164 2/20 0.51
RAB9A P51151 2/20 0.51
TPH1 P17752 2/20 0.49
POLB P06746 2/20 0.48
HDAC1 Q13547 2/20 0.48
HTT P42858 2/20 0.48
CYP1A2 P05177 1/20 0.48
CYP3A4 P08684 1/20 0.48
CYP2D6 P10635 1/20 0.48
CYP2C9 P11712 1/20 0.48
CYP2C19 P33261 1/20 0.48
ALDH1A1 P00352 2/20 0.47
HPGD P15428 1/20 0.47
MAPT P10636 3/20 0.47
NPC1 O15118 2/20 0.47
HDAC2 Q92769 1/20 0.47
HDAC8 Q9BY41 1/20 0.47
TSHR P16473 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6466700 0.82 RAB9A (0.57) LMNAATMKMT2ARAB9ATPH1
SCHEMBL27766331 0.78 KDM4E (0.50) KMT2AHDAC1ALDH1A1HPGDHDAC2
SCHEMBL31329312 0.76 BCL9 (0.57) LMNAKMT2ARAB9APOLBHTT
SCHEMBL357271 0.74 KMT2A (0.62) LMNAKMT2ARAB9AHDAC1HTT
SCHEMBL3335119 0.72 HTT (0.72) LMNAATMRAB9ATPH1POLB
SCHEMBL18105004 0.72 LMNA (0.62) LMNAATMRAB9AHDAC1HTT
SCHEMBL6328330 0.72 PPARD (0.56) LMNAATMRAB9ATPH1HTT
SCHEMBL1567346 0.71 LMNA (1.00) LMNAATMKMT2ARAB9APOLB
SCHEMBL25002919 0.71 LMNA (0.60) LMNAATMKMT2ARAB9ATPH1
SCHEMBL7952282 0.71 SIRT2 (0.72) LMNAATMKMT2ARAB9AHDAC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1423120-A4 2H-PHTHALAZIN-1-ONES AND METHODS FOR USE THEREOF ICOS CORP (US) 2005-12-28 EP disclosed
US-6924284-B2 PARP inhibitors ICOS CORPORATION (US) 2005-08-02 US disclosed
EP-1423120-A1 2H-PHTHALAZIN-1-ONES AND METHODS FOR USE THEREOF ICOS CORPORATION (US) 2004-06-02 EP disclosed
US-20040087588-A1 Parp inhibitors ICOS CORPORATION 2004-05-06 US disclosed
WO-2003015785-A1 2H-PHTHALAZIN-1-ONES AND METHODS FOR USE THEREOF ICOS CORPORATION (US) 2003-02-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040087588-A1 Parp inhibitors PARP1, PARP2, PARP11 LMNA 448/4885ATM 414/4885KMT2A 152/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.